What does BioRestorative Therapies do?
BioRestorative Therapies, Inc. is a Nasdaq-listed biotechnology company developing adult stem-cell therapies and biologic products. It has no approved therapeutic medicine; value depends on clinical evidence, regulatory progress, and access to capital or partners. The company describes work in degenerative disc disease, metabolic disorders, and regenerative aesthetics on its official corporate website.
Which programs define the company?
How should readers interpret the reporting structure?
The company reports one operating segment, so investors do not receive program-level profit, asset, or cash-flow disclosure. Analytically, BRTX-100 is a clinical and regulatory asset, ThermoStem is preclinical optionality, and BioCosmeceuticals is an early diversification effort.
| Platform | Stage at July 2026 | Primary customer or user | Economic role |
|---|---|---|---|
| BRTX-100 | Phase 2 dosing complete; blinded follow-up underway | Patients with chronic lumbar disc disease; treating physicians | Potential future product sales, licensing, or partnership economics |
| ThermoStem | Preclinical research and patent development | Future metabolic-disease patients and development partners | Long-duration pipeline optionality; no material current revenue |
| BioCosmeceuticals | Commercial launch and channel-building phase | Distributors, medical spas, physicians, and consumers | Near-term product revenue and possible manufacturing or private-label revenue |
How does BioRestorative Therapies make money today?
Current revenue is tiny relative to costs. In Q1 2026, BioRestorative generated sublicense royalties and newly launched BioX product revenue. Its Q1 2026 Form 10-Q reported $23,170 of total revenue, consisting of $11,870 of BioX product sales and $11,300 of royalties.
What is the current business model?
| Revenue stream | How it works | Q1 2026 evidence | Scalability question |
|---|---|---|---|
| Procedure royalties | Per-disc-procedure royalties under a sublicense arrangement | $11,300; down 54.8% year over year | Depends on procedure volume outside BioRestorative’s direct control |
| BioX product sales | Sales of regenerative aesthetic products to multiple customers | $11,870; first commercial revenue in Q1 2026 | Requires repeat demand, channel access, compliant claims, and attractive unit economics |
| Future therapeutic economics | Potential direct commercialization, licensing, milestones, or royalties | No approved BRTX-100 product revenue | Depends on clinical success, FDA approval, manufacturing, reimbursement, and funding |
What could become the larger economic engine?
BioCosmeceuticals may create earlier revenue, but BRTX-100 could transform scale. Licensing could reduce funding needs while transferring some upside. The April 2026 BioCosmeceutical commercialization collaboration shows that management is simultaneously trying to build a consumer and professional channel while the clinical program matures.
What does BioRestorative Therapies’ latest quarter show?
The quarter ended March 31, 2026 remained development-funded. Revenue fell 7.3% to $23,170 while operating expenses were $3.40 million. R&D fell 27.2% and G&A fell 32.4%, largely because stock compensation declined, narrowing but not eliminating the operating loss.
Which numbers are operational, and which are accounting noise?
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Revenue | $23,170 | $25,000 | BioX added product sales, but royalty revenue weakened. |
| Gross profit | $15,785 | $22,091 | The blended gross margin fell as product cost entered the mix. |
| R&D expense | $1.93M | $2.65M | Down 27.2%; trial recruitment costs rose, but stock compensation and lab costs fell. |
| G&A expense | $1.48M | $2.18M | Down 32.4%, mainly from lower stock compensation. |
| Operating loss | $(3.39M) | $(4.81M) | A 29.6% improvement, but still about 146 times quarterly revenue. |
| Net loss | $(2.15M) | $(5.34M) | Improvement was helped by a $1.22M non-cash warrant-liability fair-value gain. |
| Operating cash flow | $(3.81M) | $(2.78M) | Cash burn increased despite the smaller accounting loss. |
Why does the gross margin need context?
At March 31, 2026, cash was $3.11 million, securities were $0.48 million, and working capital was $2.19 million. Despite the $5.0 million gross February offering, cash plus securities equaled only about 0.94 times Q1 operating cash use.
Which turning points shaped BioRestorative Therapies’ current strategy?
BioRestorative’s history combines scientific optionality, regulatory persistence, capital resets, and movement toward a vertically integrated platform. The company’s 2025 Form 10-K connects the corporate history to the present pipeline.
-
1997The business was incorporated. This long history contrasts with its still-precommercial therapeutic profile and highlights how lengthy cell-therapy development can be.
-
2011The company adopted the BioRestorative Therapies name and began ThermoStem research. The metabolic platform remains a source of patents and optionality, but not a near-term earnings engine.
-
2017The FDA authorized the BRTX-100 Phase 2 study. This created the regulatory foundation for the company’s lead clinical program.
-
2022A U.S. patent related to BRTX-100 issued, and the company reincorporated in Nevada. The patent strengthened the licensed technology package supporting the spine program.
-
2024–2025ThermoStem patents expanded in Japan, Europe, Israel, and other jurisdictions, while management added commercialization leadership for BioCosmeceuticals.
-
December 2025A Type B FDA meeting addressed a potential accelerated BLA pathway and elements of a future Phase 3 program, prompting Phase 3-enabling activity.
-
February–May 2026Enrollment reached 99 patients and dosing was completed. The study moved from recruitment and treatment into blinded follow-up.
-
June 2026Manufacturing for the Phase 2 trial was completed, reinforcing management’s claim that a common cell-processing infrastructure can support both therapeutic and commercial biologic products.
What changed most recently?
Why does BRTX-100’s autologous manufacturing model matter?
BRTX-100 uses a patient’s own bone-marrow-derived mesenchymal stem cells, expanded under low oxygen, supplemented with platelet lysate, cryopreserved, and delivered by intradiscal injection. The company argues this process suits the disc environment and may reduce rejection risk. Its BRTX-100 program page explains the intended biological rationale.
What is the strategic advantage?
Consistent benefit could differentiate BRTX-100, but personalized manufacturing creates cost, quality-control, and scale challenges. The potential moat combines licensed IP, clean-room capability, process know-how, evidence, and regulatory execution.
How is the Phase 2 trial designed?
| Trial feature | Official design | Analytical importance |
|---|---|---|
| Enrollment | 99 patients | Large enough to generate a meaningful Phase 2 signal, but not definitive approval evidence. |
| Randomization | 2:1, BRTX-100 to control | Creates a controlled comparison while giving more patients active treatment. |
| Dose | 40 million cells in a single injection | Links efficacy and safety interpretation to a defined manufacturing specification. |
| Primary timing | 52-week efficacy assessment | Requires durability, not only a short-term pain response. |
| Responder definition | At least 30% improvement in VAS pain and ODI function | A dual threshold makes the endpoint clinically interpretable. |
| Follow-up | Through 104 weeks | Supports durability and longer-term safety analysis. |
The trial is registered as NCT04042844. Blinded pooled data cannot establish treatment effect. The decisive evidence will be the active-versus-control comparison after sufficient 52-week follow-up.
Who are BioRestorative Therapies’ main competitors?
Competition spans regenerative disc programs, surgery, injections, physical therapy, pain medicines, and physician inertia. ThermoStem faces a metabolic market transformed by GLP-1 therapies. BioCosmeceuticals competes on claims, brand trust, channel access, and clinical validation.
Where could BRTX-100 differentiate?
The company emphasizes autologous cells, hypoxic culture, platelet lysate, and a single injection. These may support safety and viability, but the defensible advantage would be replicated benefit in pain and function with durable follow-up and an executable regulatory path.
| Competitive force | Pressure on BRTX | Potential response |
|---|---|---|
| Regenerative disc developers | Competing clinical evidence, patents, partnerships, and regulatory timing | Demonstrate a differentiated responder rate, durability, safety, and manufacturing consistency |
| Surgery and standard care | Established reimbursement, physician familiarity, and treatment pathways | Show credible non-surgical benefit and an economically attractive treatment pathway |
| Unapproved stem-cell clinics | Faster market access without equivalent development cost | Use FDA-grade evidence, cGMP controls, and physician trust as quality differentiation |
| GLP-1 medicines | Highly effective, heavily funded metabolic competitors | Position ThermoStem around a distinct mechanism or partner rather than direct near-term scale |
| Aesthetic brands and biologic suppliers | Crowded claims, customer-acquisition cost, and rapid product cycles | Combine manufacturing, independent validation, professional channels, and repeat purchasing |
What does market position really depend on?
How financially strong is BioRestorative Therapies?
BioRestorative has no approved therapy, negligible revenue, persistent losses, and a going-concern warning. Financial strength means funding the next milestones.
What does the annual baseline show?
| Financial line | FY2025 | FY2024 | Research implication |
|---|---|---|---|
| Revenue | $359,700 | $401,000 | Down 10.3%; current revenue does not fund development. |
| Gross profit | $335,856 | $372,928 | FY2025 gross margin was 93.4%, reflecting a royalty-heavy mix. |
| R&D expense | $10.09M | $6.71M | Up 50.5%, consistent with heavier clinical activity. |
| G&A expense | $5.89M | $5.22M | Up 12.8%, including higher stock compensation and headcount cost. |
| Operating loss | $(15.65M) | $(11.56M) | The cost of advancing the pipeline widened the core loss. |
| Net loss | $(14.24M) | $(8.98M) | Other income softened, but did not change, the operating reality. |
| Operating cash flow | $(10.79M) | $(8.23M) | Cash burn increased 31.1% as the trial advanced. |
How does capital allocation affect the thesis?
The February financing issued 12,560,715 shares, 1,725,000 exercised pre-funded warrants, and 14,285,715 warrants. Shares outstanding rose from 8,876,242 to 25,478,170. Another 19,780,753 warrants and 5,213,390 options were excluded from diluted EPS, creating dilution sensitivity.
In June 2026, the company added a $1.0 million revolver at 12% interest, with a 16% default rate and one-year maturity. The related June 2026 Form 8-K shows that the lender also received director-designation rights. The financing cost and governance terms underline the company’s constrained bargaining position.
Who owns BioRestorative Therapies stock, and why does governance matter?
BioRestorative has one common share class, but beneficial ownership includes options and warrants exercisable within 60 days. The 2025 Form 10-K ownership table uses 25,478,170 shares and is dated March 23, 2026, before the June board restructuring.
Who had the largest disclosed positions?
| Holder or group | Beneficial shares | Approximate stake | Why it matters |
|---|---|---|---|
| Auctus-related group | 2,670,211 | 9.99% | A significant financing-linked position with a capped percentage. |
| Alta Partners LLC | 1,787,163 | 7.0% | A meaningful outside owner in a thinly capitalized biotechnology company. |
| Lance Alstodt, CEO and chair | 1,520,217 | 5.7% | Aligns management with equity value, but much of the position includes exercisable awards. |
| Francisco Silva | 1,463,606 | 5.5% | The ownership snapshot predates his June 2026 board resignation. |
| All directors and executive officers | 3,964,730 | 13.6% | Shows meaningful insider exposure, again including exercisable securities. |
What changed in governance during 2026?
The authorized-share amendment and executive agreements are documented in the May 2026 Form 8-K. The governance signal is mixed: management has equity exposure and multi-year contracts, but financing needs can reshape the board and expand dilution. Capital providers can become strategic actors.
What opportunities could change BioRestorative Therapies’ outlook?
The upside case depends on milestones that could alter probability, timing, capital needs, or commercial scale. The company’s May 2026 Phase 2 dosing update placed expected topline data in Q2 2027 and said Phase 3-readiness work was continuing.
Which growth drivers are most material?
Why is commercial diversification important?
BioCosmeceuticals can generate revenue without the same clinical timeline, but it faces acquisition-cost, claims, branding, and channel risks. Repeat demand through spas, physicians, distributors, consumers, or private label could offset some overhead and reduce dependence on one clinical asset.
What risks could weaken the BioRestorative Therapies story?
Risk is concentrated. Clinical disappointment, regulatory delay, manufacturing problems, or financing interruption could impair development. The 2025 Form 10-K said available funds were insufficient for planned development and included substantial doubt about the company’s ability to continue as a going concern.
Which risks are most decision-relevant?
What is the central strategic tension?
Progress can increase asset value, but each development step consumes cash before therapeutic revenue exists. The outcome depends on both whether BRTX-100 works and the terms used to finance a registrational path.
Why does BioRestorative Therapies matter for valuation?
Current revenue multiples and near-term free-cash-flow DCFs are weak tools because therapeutic value is probability-weighted and cash flow is negative. A better framework combines risk-adjusted pipeline value with separate BioCosmeceutical value, then subtracts corporate costs, development spending, debt, and dilution.
Which variables should a DCF or rNPV model emphasize?
BioCosmeceuticals can be modeled from customers, order frequency, average order value, manufacturing cost, and channel spending. It should not be used as evidence for BRTX-100; each asset needs separate assumptions and discounting.
What is the key takeaway from BioRestorative Therapies analysis?
BioRestorative has one company-defining clinical program, one preclinical option, and one early commercial platform. Its key achievement is completing enrollment, dosing, and manufacturing for the 99-patient BRTX-100 Phase 2 study. The unresolved question is whether the active arm will outperform control after unblinding.
The company remains capital-market dependent: FY2025 operating cash use was $10.79 million, Q1 2026 use was $3.81 million, and the share count nearly tripled by March 31, 2026. The revolver added liquidity and lender-linked board influence. Clinical progress and financing structure must be analyzed together.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.